大肠癌临床分期相关蛋白的蛋白质组学研究

目的：筛选与大肠癌临床分期相关的蛋白，为大肠癌分子分期和预后预测提供依据。方法：将不同临床分期大肠癌组织蛋白进行二维凝胶电泳，选择部分差异表达蛋白进行MALDI-TOF质谱分析和生物信息学分析以鉴定差异表达蛋白;免疫组织化学方法验证筛选结果。结果： 建立了不同临床分期大肠癌组织的二维凝胶电泳图谱，其中Ⅰ，Ⅱ，Ⅲ，Ⅳ大肠癌组织平均蛋白质点数分别为970±41,980±32,1010±43,1240±34;以Ⅰ期大肠癌为参照，Ⅱ期大肠癌差异表达蛋白有52.00±12，Ⅲ期大肠癌差异表达蛋白42.00±11，Ⅳ期大肠癌差异表达蛋白72.00±15，通过进行质谱分析和生物信息学查询，鉴定30个显著差异表达的蛋白点，其中Ⅱ，Ⅲ，Ⅳ均上调的有3种蛋白：AnnexinⅡ,AnnexinⅣ,热休克蛋白27(HSP27)。而仅在Ⅳ期中上调蛋白有1种蛋白,即肝脂肪酸结合蛋白（LFABP)。AnnexinⅡ和肝型脂肪酸结合蛋白表达的免疫组化检测结果与蛋白质筛选结果基本一致。结论：不同临床分期的大肠癌中存在着差异表达蛋白，这些蛋白可能作为大肠癌分子分期和预后的标志物。     

腹腔镜辅助胃底贲门癌根治术：附22例报告

目的探讨腹腔镜辅助下行D2式胃底贲门癌根治术的临床效果。方法回顾性分析3年间行腹腔镜辅助下胃底贲门癌根治术22例患者的临床资料。全组均行腹腔镜辅助下近端胃大部切除术。结果无中转开腹,平均手术时间188(162~270)min。术中平均出血182(100~260)mL。淋巴结清扫18.6(10~32)枚。术后患者平均胃肠道功能恢复时间78(48~140)h。1例肿瘤侵犯食管下段的患者术后发生吻合口瘘,经留置空肠营养管、抗炎、充分引流等处理后4周痊愈。无手术死亡。全组术后随访1~37个月,平均9.2个月,无复发转移病例。结论腹腔镜辅助下行D2式胃底贲门癌根治术方法可行,效果好,具有视野清晰、创伤小、出血少、恢复快等优点。     

Benign liver lesions: implications of detection in cancer patients

A review of liver sonograms obtained for cancer patients (excluding primary liver cancers) over a 12 year period found 829 benign lesions: non-parasitic cysts (427 cases), hemangiomas (216 cases), solitary calcifications (79 cases), focal fatty infiltration (62 cases), and miscellaneous lesions (45 cases). These benign pathologies represented 41.8% of the focal hepatic lesions observed during this period in this population; hepatic metastases accounted for the remaining 58.2%. Marked female predilection was noted for the nonparasitic cysts, hemangiomas, and focal fatty infiltration; 63–78.7% of these lesions were solitary, and first-line imaging by US was sufficient for diagnosis of 66.1–98.2% of cases. Analysis of lesion evolution over more than 5 years revealed modifications in 17% of hemangiomas, 23.9% of nonparasitic cysts, and 75% of cases of focal fatty infiltration. Systematic pretherapy liver sonography can be proposed owing to the high frequency of benign liver lesions that can create diagnostic problems during follow-up of cancer patients. Correspondence to: J. N. Bruneton     

放疗同期卡莫氟化疗治疗局部中晚期鼻咽癌的Ⅲ期临床观察

目的:探讨患者对联合应用诱导化疗和放疗同期口服卡莫氟治疗局部中晚期鼻咽癌疗效和不良反应.方法:收治66例局部中晚期鼻咽癌患者,随机分为两组,诱导化疗随后放疗组简称为对照纽,诱导化疗随后放疗同期卡莫氟治疗组简称为治疗组.两组患者数均为33例.进行根治性放疗前两组患者均接受两个疗程诱导化疗.治疗组在放疗期间同时口服卡莫氟.结果:诱导化疗有效率高,平均有效率高达87%,其中平均完全缓解率(CR)为8.7%、不完全缓解率(PR)为78.4%.对照组鼻咽肿瘤、颈部转移淋巴结全消平均剂量均高于治疗组,统计学有差异.放疗后3个月治疗组鼻咽、颈部转移淋巴结CR均高于对照组(p=0.016,P=0.042).随访期内治疗组患者局部复发率和远处转移率有降低趋势.临床治疗中出现的主要毒副反应为白细胞下降、口腔粘膜炎、急性放射性皮炎及由卡莫氟引起的热感、尿频、头昏等.结论:放疗同期口服卡莫氟治疗局部中晚期鼻咽癌,降低了鼻咽和颈部肿瘤完全消退的照射剂量,提高了鼻咽肿瘤和颈部转移灶的完全缓解率,局部复发率和远处转移率有下降趋势.尽管加卡莫氟患者毒的副作用加重,但可以耐受,经对症处理绝大部分患者能按计划完成治疗.在鼻咽癌同步化放疗方案中卡莫氟的推荐剂量为600mg/d,分3次口服.放疗同期口服卡莫氟治疗的远期疗效有待于进一步观察.     

Treatment of malignant dysphagia with nitinol stents

Self-expanding nitinol stents were used in 22 patients for palliative treatment of malignant esophagogastric strictures. All patients but 5 were men (age range 47–75 years). The strictures were caused by squamous cell carcinoma (n = 12), adenocarcinoma (n = 8), and recurrent anastomotic carcinoma (n = 2). No technical failure or procedural complications occurred. After the procedure, the severity of dysphagia decreased at least one grade in all patients. Tumor ingrowth into the stent was seen in 7 patients of 22 (32%). Four of these patients were treated with additional stents, and in 3 patients, due to refusal, only balloon dilations were performed, which caused temporary relief. Tumor ingrowth into the stent was noted from 10 days to 7 months (mean 3 months). This seems to be a disadvantage of nitinol stents. At the end of the study 10 patients had died dead with a mean survival of 3 months (range 1 week to 6 months) and 12 patients were still alive with a mean follow-up of 4 months (range 1–8 months). It is concluded that nitinol stents provide satisfactory palliation in patients with malignant dysphagia with neglectable procedural morbidity and mortality rates.     

A rare case of nasopharyngeal angiofibroma in an elderly female

Nasopharyngeal angiofibromas occur predominantly in males in their puberty and adolescence; the incidence in other age groups and in women is exceptional. This report describes a case of a 57-year-old woman with nasopharyngeal angiofibroma presenting typical radiological findings in computed tomography, MR imaging and angiography. The tumour was successfully removed and histopathological examination confirmed the diagnosis. In 6 years follow-up the patient is free of symptoms.     

上调Mg2+/Mn2+依赖性蛋白磷酸酶1F表达对鼻咽癌HONE-1细胞增殖和迁移的影响

目的 探讨上调Mg²⁺/Mn²⁺依赖性蛋白磷酸酶1F（PPM1F）对鼻咽癌HONE-1细胞增殖、迁移的影响,并阐明其作用机制。 方法 鼻咽癌HONE-1细胞分为pcDNA3.1组（转染pcDNA3.1质粒）和pcDNA3.1-Flag-PPM1F组（转染pcDNA3.1-Flag-PPM1F质粒）。实时荧光定量PCR（RT-qPCR）法和Western blotting法检测2组细胞中PPM1F和E-钙黏蛋白（E-cadherin）mRNA及蛋白表达水平,CCK-8法和克隆形成实验检测2组细胞增殖活性和克隆形成率,细胞划痕实验检测2组细胞划痕愈合率,Transwell实验检测2组细胞中迁移细胞数。 结果 与pcDNA3.1组比较,pcDNA3.1-Flag-PPM1F 组细胞中PPM1F mRNA表达水平明显升高（P<0.01）,且PPM1F蛋白表达量明显增加,细胞中E-cadherin mRNA和蛋白表达水平明显升高（P<0.01）,细胞增殖活性、克隆形成率和划痕愈合率明显降低（P<0.05或P<0.01）,迁移细胞数明显减少（P<0.05）。 结论 上调PPM1F表达能够抑制鼻咽癌HONE-1 细胞增殖和迁移,其机制可能与细胞间的黏附作用有关。     

不同来源潜伏膜蛋白1基因转染对鼻咽癌CNE1细胞生长的影响

目的:探讨不同来源的EB病毒潜伏膜蛋白1(LMP1)基因转染对人高分化鼻咽癌(NPC)细胞系CNE1生长的影响。方法:采用脂质体介导法分别将含有来源于B95-8淋巴细胞标准株的LMP1基因(B95-8-LMP1)和来源于NPC组织的LMP1基因(CAO-LMP1)的质粒转染CNE1;RT-PCR和蛋白印迹法分别鉴定LMP1mRNA和蛋白表达;结晶紫法、流式细胞术和平板克隆形成法测定不同来源的LMP1对CNE1生长特性的影响。结果:成功建立稳定表达不同来源LMP1的CNE1细胞系。两种不同来源的LMP1均可促进CNE1细胞的生长(P<0.01);CAO-LMP1比B95-8-LMP1具有更强促进CNE1生长的作用(P<0.01)。结论:不同来源LMP1对CNE1的体外生长均有促进作用,CAO-LMP1比B95-8-LMP1具有更强的促增殖能力。     

荷人鼻咽癌裸鼠血浆MDA,cAMP／cGMP水平及PSP的影响

本实验利用ＢＡＬＢ／Ｃ裸小鼠，复制荷人鼻咽癌裸鼠模型，检测荷瘤鼠血浆丙二醛，ｃＡＭＰ，ｃＧＭＰ和ｃＡＭＰ／ｃＧＭＰ比值，观察云芝糖肽对荷人ＮＰＣ裸鼠的抑瘤作用及对荷瘤鼠血浆ＭＤＡ和ｃＡＭＰ／ｃＧＭＰ等的影响。结果发现荷瘤鼠血浆ＭＤＡ升高，ｃＡＭＰ，ｃＧＭＰ降低，ｃＡＭＰ／ｃＧＭＰ比值升高，高你低浓度ＰＳＰ对荷人ＮＰＣ裸鼠均有明显抗癌作用（Ｐ＜０．０１），抑瘤率５９．５８－９５．５３％；并可降低荷瘤     

湖南汉族人群HLA-DR位点等位基因多态性与鼻咽癌的相关性研究

目的：探讨湖南汉族人群HLA-DR位点等位基因多态性与鼻咽癌遗传易感性之间的关系。 方法： 应用PCR/SSO基因分型技术对93例湖南汉族鼻咽癌患者和93例健康对照作HLA-DRB1、-DRB3、-DRB4、-DRB5基因分型，采用χ2检验比较两组各位点等位基因频率、单倍型频率分布的差异。 结果： NPC组DRB1*1101明显低于对照组，DRB1*0801明显高于对照组, 但P值经Bonferroni校正后，差异均无显著（Pc>0.05）。 结论： 湖南汉族人群HLA-DR位点与鼻咽癌无明显相关。